ODX.L Regulatory News (ODX)

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

Further positive data for Mologic COVID-19 lateral flow antigen test

Mologic test shows high diagnostic accuracy (specificity and sensitivity)

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the Mologic COVID-19 lateral flow antigen test has been independently verified in a 665-person study in Germany by FIND a global not-for-profit foundation. The test was shown to demonstrate best-in-class performance with 100% specificity and 96.4% sensitivity (Cycle threshold

FIND (www.finddx.org), is a World Health Organization collaborating centre for laboratory strengthening and diagnostic technology evaluation and seeks to find diagnostic solutions to overcome diseases of poverty in lower- and middle-income countries.

The report is available to read here:

https://www.finddx.org/wp-content/uploads/2021/04/Mologic_Ag-Public-Report_v1-20210423.pdf

Omega has CE-Marked the Mologic lateral flow antigen test for COVID-19 and has launched the test for professional-use under Omega's VISITECT® brand. The VISITECT® COVID-19 Antigen test provides healthcare professionals with an accurate rapid test for the detection of the nucleoprotein of the SARS-CoV-2 virus in respiratory swabs in 10 minutes.  

For further information please visit: VISITECT® COVID-19 Antigen Test | Omega Diagnostics

Colin King, CEO of Omega, commented: "This is great news for the Mologic test, which we are now producing under our VISITECT brand. It is significant that the test has been shown to have high diagnostic accuracy on self-collected swab specimens. Rapid diagnostic tests play a crucial role in breaking the spread of infection in the community and we are delighted to be a leading manufacturer of these home-grown tests."

 Contacts: